Veraxa Biotech is trading 10.26% down at $1.75 amid broader weakness across biotechnology shares.
- The company announced positive early antibody-oligonucleotide conjugate research results with Secarna Pharmaceuticals on August 24, 2026.
- The results remain preliminary, with discussions about next steps still ongoing.
- The update does not explain the decline.